BiotechTube

tividenofusp alfa + idursulfase

Phase 2/3Recruiting
0 watching 0 views this week📈 Rising
60
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mucopolysaccharidosis II

Conditions

Mucopolysaccharidosis II

Trial Timeline

Jul 21, 2022 → Dec 1, 2027

NCT ID
NCT05371613

About tividenofusp alfa + idursulfase

tividenofusp alfa + idursulfase is a phase 2/3 stage product being developed by Denali Therapeutics for Mucopolysaccharidosis II. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05371613. Target conditions include Mucopolysaccharidosis II.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT05371613Phase 2/3Recruiting

Competing Products

20 competing products in Mucopolysaccharidosis II

See all competitors
ProductCompanyStageHype Score
OdiparcilInventivaPhase 2
47
anakinraSwedish Orphan BiovitrumPhase 1/2
40
laronidaseSanofiApproved
84
LaronidaseSanofiApproved
84
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 2
51
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
84
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)SanofiPhase 1/2
40
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
76
rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
76
Aldurazyme + Aldurazyme + placeboSanofiPhase 3
76
LaronidaseSanofiApproved
84
JR-141JCR PharmaceuticalsPhase 2/3
64
JR-441 + JR-441 + JR-441JCR PharmaceuticalsPhase 1/2
40
JR-446JCR PharmaceuticalsPhase 1/2
40
JR-171JCR PharmaceuticalsPhase 1/2
40
JR-141JCR PharmaceuticalsPhase 2
51
JR-141 + Idursulfase + JR-141 or IdursulfaseJCR PharmaceuticalsPhase 3
76
JR-141JCR PharmaceuticalsPhase 3
76
JR-171 (lepunafusp alfa)JCR PharmaceuticalsPhase 1/2
40
JR-141JCR PharmaceuticalsPhase 1/2
40

Other Products from Denali Therapeutics

tividenofusp alfaPhase 2/3
60
DNL343 + Matching PlaceboPhase 2/3
60
DNL593 + PlaceboPhase 1/2
36
tividenofusp alfaPhase 1/2
36
DNL126Phase 1/2
36